IL1B and type 1 diabetes mellitus: The blockade of IL-1 action reduced the incidence of T1DM in animals, and clinical trials have been started to study the feasibility, safety and efficacy of IL-1 therapy in T1DM patients (Tack et al., 2009; Mandrup-Poulsen et al., 2010).